학술논문

Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy.
Document Type
article
Source
Stem cell reports. 10(3)
Subject
Muscle
Skeletal
Myocardium
Myocytes
Cardiac
Animals
Mice
Inbred C57BL
Mice
Inbred mdx
Humans
Mice
Muscular Dystrophy
Duchenne
Disease Models
Animal
Muscular Dystrophy
Animal
Dystrophin
Female
Male
Exosomes
Induced Pluripotent Stem Cells
Cell- and Tissue-Based Therapy
cardiomyopathy
cardiosphere-derived cells
dystrophin
exosomes
microRNA
muscular dystrophy
Heart Disease
Regenerative Medicine
Intellectual and Developmental Disabilities (IDD)
Pediatric Research Initiative
Stem Cell Research
Brain Disorders
Stem Cell Research - Induced Pluripotent Stem Cell
Muscular Dystrophy
Rare Diseases
Duchenne/ Becker Muscular Dystrophy
Cardiovascular
Pediatric
Development of treatments and therapeutic interventions
Aetiology
2.1 Biological and endogenous factors
5.2 Cellular and gene therapies
Musculoskeletal
Biochemistry and Cell Biology
Clinical Sciences
Language
Abstract
Genetic deficiency of dystrophin leads to disability and premature death in Duchenne muscular dystrophy (DMD), affecting the heart as well as skeletal muscle. Here, we report that clinical-stage cardiac progenitor cells, known as cardiosphere-derived cells (CDCs), improve cardiac and skeletal myopathy in the mdx mouse model of DMD. Injection of CDCs into the hearts of mdx mice augments cardiac function, ambulatory capacity, and survival. Exosomes secreted by human CDCs reproduce the benefits of CDCs in mdx mice and in human induced pluripotent stem cell-derived Duchenne cardiomyocytes. Surprisingly, CDCs and their exosomes also transiently restored partial expression of full-length dystrophin in mdx mice. The findings further motivate the testing of CDCs in Duchenne patients, while identifying exosomes as next-generation therapeutic candidates.